Author Year




Yüklə 27.75 Kb.
tarix28.02.2016
ölçüsü27.75 Kb.
eTable 1: Recent meta-analyses of randomized clinical trials investigating chemotherapy in patients with advanced/metastatic gastric cancer

Author

Year

Type of data

No. of

trials

No. of

patients

Compared regimens

Relative risk

for OS (95% CI)

Montagnani et al.

2011

Published data

3

1294

oxaliplatin vs cisplatin

0.88 (0.78, 0.99)

Wagner et al.

2010

Published data

35

5726

  1. chemo vs best supportive care (n=124)

  2. Any combination vs single agent (n=1914)

  3. 5FU/cisplatin w vs w/o anthra (n=501)

  4. 5FU/anthracyclines w vs w/o platinum [check] (n=1147)

  5. with vs w/o irinotecan (n=639)

  6. with vs w/o docetaxel (n=805)

1. 0.37 (0.24, 0.55)

2. 0.82 (0.76, 0.90)

3. 0.77 (0.62, 0.85)

4. 0.82 (0.73-0.92)

5. 0.86 (0.73, 1.02)

6. 0.93 (0.75, 1.15)



Okines et al

2009

Individual data

2

1318

capecitabine-based vs 5FU-based combination

0.87 (0.77, 0.98)

Chau et al

2009

Individual data

4

833

(Gastric cancer only)



FAMTX vs ECF

EOX vs ECF



1.56 (1.17, 2.09)

0.79 (0.63, 1.00)


w/o, without

chemo, chemotherapy

5FU, 5 fluorouracil

ECF, epirubicin, cisplatin and 5FU

FAMTX, 5FU, doxorubicin and methotrexate

EOX, epirubicin, oxaliplatin and capecitabine

eTable 2: Search strategy filter

1. randomized controlled trial.pt.

2. controlled clinical trial.pt.

3. randomized controlled trials/

4. random allocation/

5. double blind method/

6. single blind method/

7. or/1-6

8. animals/ not (animals/ and human/)

9. 7 not 8

10. exp stomach neoplasms/

11. (stomach adj5 neoplas$).tw.

12. (stomach adj5 cancer$).tw.

13. (stomach adj5 carcin$).tw.

14. (stomach adj5 tumo$).tw.

15. (stomach adj5 metasta$).tw.

16. (stomach adj5 malig$).tw.

17. (stomach adj5 advanc$).tw.

18. (gastric adj5 neoplas$).tw.

19. (gastric adj5 cancer$).tw.

20. (gastric adj5 carcin$).tw.

21. (gastric adj5 tumo$).tw.

22. (gastric adj5 metasta$).tw.

23. (gastric adj5 malig$).tw.

24. (gastric adj5 advanc$).tw.

25. or/10-24

26. exp drug therapy/

27. exp chemotherapy adjuvant/

28. exp drug therapy combination/

29. exp antineoplastic agents combined/

30. chemothera$.tw.

31. exp chemotherapy/

32. or/26-31

33. exp palliative care/

34. palliat$.tw.

35. unresect$.tw.

36. inopera$.tw.

37. advanc$.tw.

38. (best adj5 support$ adj5 care).tw.

39. unoperable.tw.

40. (non adj5 resect$).tw.

41. or/33-39

42. 25 and 32

43. 41 and 42

44. 9 and 43

eTable 3: Difference in background characteristics between included and non-included trials




 Characteristic

Factor

Trial

Not Received

Received

Area

Asian

7 (21.9 %)

6 (26.1 %)

Europe

18 (56.3 %)

12 (52.2 %)

United States

7 (21.9 %)

5 (21.7 %)

Median age

Median (min,max)

59.5 (48-72)

60 (55-65)

% of PS>=2

Median (min,max)

26.1% (3.0-87.7)

12.0% (0-39.7)

% of males

Median (min,max)

70.4% (40.6-85.3)

73.2% (58.6-82.6)

% of metastasis

Median (min,max)

83.3% (28.4-100)

92.1% (20.4-98.5)

Year last pts enrolled

Median (min,max)

1992 (1979-2006)

1998 (1980-2006)

Year published

Median (min,max)

1995 (1982-2011)

2003 (1984-2009)



Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©www.azrefs.org 2016
rəhbərliyinə müraciət

    Ana səhifə